Latanoprost concentration (μg/mL) | ||||
---|---|---|---|---|
50 | 75 | 100 | 125 | |
ITT Population, N | 71 | 70 | 72 | 69 |
Sex, n (%) | ||||
Male | 32 (45.1) | 35 (50.0) | 42 (58.3) | 35 (50.7) |
Female | 39 (54.9) | 35 (50.0) | 30 (41.7) | 34 (49.3) |
Race, n (%) | ||||
Caucasian | 56 (78.9) | 57 (81.4) | 55 (76.4) | 56 (81.2) |
Black | 1 (1.4) | 0 (0) | 2 (2.8) | 1 (1.4) |
Asian | 14 (19.7) | 13 (18.6) | 15 (20.8) | 12 (17.4) |
Age (years) | ||||
Mean ± SD | 59.5 ± 12.8 | 59.5 ± 12.0 | 60.6 ± 13.8 | 61.2 ± 12.7 |
Median | 61.0 | 59.0 | 60.5 | 63.0 |
Range | 20-82 | 26-85 | 20-85 | 26-89 |
Study eye, n (%) | ||||
Right | 16 (22.5) | 15 (21.4) | 13 (18.1) | 11 (15.9) |
Left | 8 (11.3) | 8 (11.4) | 11 (15.3) | 16 (23.2) |
Both | 47 (66.2) | 47 (67.1) | 48 (66.7) | 42 (60.9) |
Treated eye, n (%) | ||||
Right | 7 (9.9) | 5 (7.1) | 3 (4.2) | 4 (5.8) |
Left | 1 (1.4) | 1 (1.4) | 2 (2.8) | 4 (5.8) |
Both | 63 (88.7) | 64 (91.4) | 67 (93.1) | 61 (88.4) |
Worse eye, n (%) | ||||
Right | 50 (70.4) | 43 (61.4) | 39 (54.2) | 36 (52.2) |
Left | 21 (29.6) | 27 (38.6) | 33 (45.8) | 33 (47.8) |
Eye color, n (%) | ||||
Homogenous blue, gray or green | 8 (11.3) | 11 (15.7) | 4 (5.6) | 11 (15.9) |
Homogenous brown | 45 (63.4) | 43 (61.4) | 46 (63.9) | 40 (58.0) |
Blue-brown or gray-brown | 10 (14.1) | 12 (17.1) | 11 (15.3) | 11 (15.9) |
Green-brown | 4 (5.6) | 3 (4.3) | 8 (11.1) | 4 (5.8) |
Yellow-brown | 3 (4.2) | 1(1.4) | 3 (4.2) | 3 (4.3) |
Different* | 1 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Diagnosis † , n (%) | ||||
Primary open-angle glaucoma | 53 (74.6) | 44 (62.9) | 47 (65.3) | 47 (68.1) |
Ocular hypertension | 16 (22.5) | 18 (25.7) | 21 (29.2) | 16 (23.2) |
Different* | 2 (2.8) | 8 (11.4) | 4 (5.6) | 6 (8.7) |
IOP-lowering medication at | ||||
screening, n% | ||||
Alpha agonists | 3 (4.2) | 5 (7.1) | 6 (8.3) | 1 (1.4) |
Beta-blockers | 33 (46.5) | 28 (40.0) | 26 (36.1) | 23 (33.3) |
Carbonic anhydrase inhibitors | 7 (9.9) | 8 (11.4) | 2 (2.8) | 2 (2.9) |
Combination drugs | 9 (12.7) | 6 (8.6) | 4 (5.6) | 5 (7.2) |
Parasympathomimetics | 0 (0.0) | 1 (1.4) | 0 (0.0) | 2 (2.9) |
Prostaglandins | 23 (32.4) | 19 (27.1) | 20 (27.8) | 20 (29.0) |
Sympathomimetics | 1 (1.4) | 1 (1.4) | 0 (0.0) | 0 (0.0) |
PP Population, N | 69 | 66 | 71 | 68 |
Baseline IOP | ||||
Worse eye 8 a.m. | ||||
Mean ± SD | 26.9 ± 3.1 | 26.6 ± 3.0 | 26.5 ± 2.5 | 26.8 ± 2.8 |
Range | 24.0 – 36.0 | 24.0 – 36.0 | 24.0 – 35.0 | 24.0 – 36.0 |
4 p.m. | ||||
Mean ± SD | 25.3 ± 3.6 | 24.6 ± 3.5 | 25.3 ± 3.1 | 25.7 ± 3.7 |
Range | 16.5 – 37.0 | 15.0 –35.0 | 17.5 – 34.0 | 18.0 – 36.0 |
Study eye | ||||
8 a.m. | ||||
Mean ± SD | 26.5 ± 2.8 | 26.1 ± 2.5 | 26.2 ± 2.4 | 26.4 ± 2.4 |
Range | 24.0 – 34.0 | 24.0 – 36.0 | 24.0 – 35.0 | 24.0 – 34.0 |
4 p.m. | ||||
Mean ± SD | 25.1 ± 3.4 | 24.3 ± 3.1 | 25.1 ± 2.9 | 25.3 ± 3.3 |
Range | 16.5 – 35.0 | 15.5 – 34.0 | 18.0 – 34.0 | 18.0 – 36.0 |